molecules of the month

Kronos CDK9 Inhibitor

selective CDK9 inhibitor

oral Ph. I candidate for MYC-amp tumors

from microarray binding assay with lysate


Kronos Bio, Cambridge, MA

Kronos Bio CDK9 inhibitor selective structure drug hunter molecules of the year KB-0742
2 mins read

The Kronos CDK9 inhibitor, KB-0742, is an ultraselective inhibitor of cyclin-dependent kinase CDK9. The CDK family of kinases have been pursued as cancer drug targets for decades, but family selectivity within the highly conserved kinase family has made it difficult to identify highly selective molecules, resulting in less than ideal tolerability. The molecule has a remarkably efficient, simple structure, rare among selective kinase inhibitors. The nearest off-targets are CDK13 and CDK2 with >60x selectivity, and it is selective against all other CDKs with >200x selectivity (including CDKs 1, 7, 4, and 6). It is currently in Ph. I for MYC-amplified solid tumors.Kronos published the discovery story and preclinical evaluation of this selective CDK9 inhibitor in Cell Chemical Biology in early…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: